ATAI

Investor Moves

Name	Value	Action	Change	Price	Current Price
Cathie WoodARK Invest $321k70.7k shares SellQ3 2026 $321k70.7k shares $4.54 $7.18
Cathie WoodARK Invest $5M1.1M shares SellQ3 2026 $5M1.1M shares $4.49 $7.18

Insider Trades

Name	Value	Action	Price	Current Price
Apeiron Investment Group Ltd.10 Percent Owner $19M8.7M shares BuyAug 14, 2025 $2.19 $7.18
Apeiron Investment Group Ltd.10 Percent Owner $3M1.8M shares BuyMar 24, 2025 $1.40 $7.18
Rao SrinivasSee Remarks $102k75.4k shares SellMar 21, 2025 $1.35 $7.18
Kirpekar SahilChief Business Officer $66k48.6k shares SellMar 21, 2025 $1.35 $7.18
Johnson Anne NagengastChief Financial Officer $45k33.5k shares SellMar 21, 2025 $1.35 $7.18
Short Glenn FrankChief Scientific Officer $18k13.2k shares SellMar 21, 2025 $1.35 $7.18

News

proactiveinvestors.comNike bets big on Beautiful Game ahead of World Cupproactiveinvestors.comJun 5

proactiveinvestors.comStrong jobs data roils markets as Fed rate cut case weakensproactiveinvestors.comJun 5

proactiveinvestors.comAtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' ratingproactiveinvestors.comJun 4

proactiveinvestors.comMYR Group to acquire Valley Electric and Comet Electric for $328Mproactiveinvestors.comMay 28

proactiveinvestors.comAtaiBeckley launches mental health patient impact grant programproactiveinvestors.comMay 28

Trade ATAI

About Atai Beckley Inc.

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.

CEO: Christian Angermayer
IPO Date: Jun 18, 2021

Market Data

Open: $4.18
High: $4.22
Low: $4.00
Volume: 6.6M
Avg Volume: 5.8M
52W High: $6.75
52W Low: $2.00

Valuation

Market Cap: $1.5B
Enterprise Value: $1.5B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$103.6M
Revenue: $4.1M
Net Income: -$660M
Cash: $85.3M
Debt: $2.1M

Events

EarningsAug 13

EPS est. -0.1